BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Ischemia
,
Prostate
,
Amniocentesis
,
Quercetin
,
rs3825942
,
SIRT1
,
cell-cell adhesion
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
claudin 1
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Skin
Peritoneum
Fallopian tube
Liver
Fetal liver
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Congenital anomaly of integument
Alopecia
Musculoskeletal function
Multiple organ failure
Malignant tumor of intestine
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
KDELR1 protein, human
BODIPY
Lymphotoxin-beta
17-hydroxyandrostane-3-glucuronide
Diamide
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
NISCH
RIMS3
TRPC6
LCP2
GADD45A
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression.
CLDN1 knock out keratinocytes as a model to investigate multiple skin disorders.
Micro RNA-175 Targets Claudin-1 to Inhibit Madin-Darby Canine Kidney Cell Adhesion.
PC (16:0/14:0) ameliorates hyperoxia-induced bronchopulmonary dysplasia by upregulating claudin-1 an…
Development of tight junction-strengthening compounds using a high-throughput screening system to ev…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Role of Urinary Claudin-2, Caveolin-1, and EGF as Diagnostic Biomarkers of Necrotizing Enterocolitis…
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Ca…
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ